Triamcinolone hexacetonide

Aristospan (triamcinolone hexacetonide) is a small molecule pharmaceutical. Triamcinolone hexacetonide was first approved as Aristospan on 1982-01-01. It is used to treat adrenal insufficiency, allergic rhinitis perennial, ankylosing spondylitis, atopic dermatitis, and berylliosis amongst others in the USA.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
infections	D007239
musculoskeletal diseases	D009140
digestive system diseases	D004066
respiratory tract diseases	D012140
otorhinolaryngologic diseases	D010038
nervous system diseases	D009422
eye diseases	D005128
urogenital diseases	D000091642
hemic and lymphatic diseases	D006425
hereditary congenital and neonatal diseases and abnormalities	D009358

Show 7 more

Trade Name

FDA

EMA

No data

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Triamcinolone hexacetonide

Tradename	Company	Number	Date	Products
ARISTOSPAN	Sandoz	N-016466 DISCN	1982-01-01	2 products, RLD

Hide discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
hexatrione	unapproved drug for use in drug shortage	2023-01-10

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
atopic dermatitis	EFO_0000274	D003876	L20
ulcerative colitis	EFO_0000729	D003093	K51
ankylosing spondylitis	EFO_0003898	D013167	M45
nephrotic syndrome	EFO_0004255	D009404	N04
multiple sclerosis	EFO_0003885	D009103	G35
uveitis	HP_0000554	D014605	H20.9
inflammation	MP_0001845	D007249	—
pulmonary tuberculosis	EFO_1000049	D014397	A15
adrenal insufficiency	—	D000309	—
systemic lupus erythematosus	HP_0002725	D008180	M32

Show 17 more

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

No data

HCPCS

Code	Description
J3303	Injection, triamcinolone hexacetonide, per 5 mg

Clinical

Clinical Trials

982 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Osteoarthritis	D010003	EFO_0002506	M15-M19	7	17	14	30	28	92
Macular edema	D008269	—	—	13	21	29	6	21	82
Knee osteoarthritis	D020370	EFO_0004616	M17	6	17	12	22	17	68
Edema	D004487	HP_0000969	R60.9	11	17	24	5	12	63
Breast neoplasms	D001943	EFO_0003869	C50	2	19	18	1	11	46
Bursitis	D002062	EFO_1000941	M71.9	2	1	2	2	36	43
Syndrome	D013577	—	—	1	7	4	5	27	42
Lichen planus	D008010	—	L43	9	5	3	7	11	35
Oral lichen planus	D017676	—	—	9	5	3	7	10	34
Macular degeneration	D008268	EFO_0001365	H35.30	4	9	8	2	6	26

Show 176 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Lymphoma	D008223	—	C85.9	7	10	2	—	3	18
Diabetic retinopathy	D003930	EFO_0003770	—	6	6	7	—	2	17
Leukemia	D007938	—	C95	6	10	2	—	—	15
Graft vs host disease	D006086	—	D89.81	2	6	1	—	2	10
Myelodysplastic syndromes	D009190	—	D46	—	5	2	—	—	7
Gouty arthritis	D015210	—	—	—	1	4	—	1	6
Posterior uveitis	D015866	EFO_1001119	—	1	2	2	—	2	6
Pars planitis	D015868	EFO_1001088	H30.2	1	3	3	—	1	6
Myeloid leukemia	D007951	—	C92	1	2	2	—	—	5
Hodgkin disease	D006689	—	C81	2	2	2	—	—	5

Show 71 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Asthma	D001249	EFO_0000270	J45	—	2	—	—	4	6
T-cell lymphoma	D016399	—	—	1	4	—	—	—	5
T-cell lymphoma cutaneous	D016410	—	—	1	2	—	—	1	4
T-cell lymphoma peripheral	D016411	—	—	—	3	—	—	—	3
Triple negative breast neoplasms	D064726	—	—	—	2	—	—	1	3
Therapeutics	D013812	—	—	—	1	—	—	1	2
Exanthema	D005076	HP_0000988	—	—	2	—	—	—	2
Mycoses	D009181	—	B35-B49	—	1	—	—	1	2
Mycosis fungoides	D009182	—	C84.0	—	1	—	—	1	2
Stomach neoplasms	D013274	EFO_0003897	C16	1	1	—	—	1	2

Show 58 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Neuralgia	D009437	EFO_0009430	—	1	—	—	—	2	3
Paranasal sinus diseases	D010254	—	—	1	—	—	—	1	2
Glandular and epithelial neoplasms	D009375	—	—	2	—	—	—	—	2
Myoepithelioma	D009208	—	—	2	—	—	—	—	2
Burns	D002056	—	T30.0	1	—	—	—	1	2
Leiomyoma	D007889	HP_0000131	D25	1	—	—	—	—	1
Adenomyosis	D062788	EFO_1001757	N80.0	1	—	—	—	—	1
Plasma cell neoplasms	D054219	—	—	1	—	—	—	—	1
Squamous cell carcinoma of head and neck	D000077195	—	—	1	—	—	—	—	1
Vasoconstriction	D014661	—	—	1	—	—	—	—	1

Show 13 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Membranous glomerulonephritis	D015433	EFO_0004254	N03.2	—	—	—	—	5	5
Migraine disorders	D008881	EFO_0003821	G43	—	—	—	—	4	4
Mastitis	D008413	EFO_1001034	N61	—	—	—	—	4	4
Acne vulgaris	D000152	EFO_0003894	L70	—	—	—	—	4	4
Granulomatous mastitis	D058890	—	N61.2	—	—	—	—	3	3
Physical therapy modalities	D026741	—	—	—	—	—	—	3	3
Rehabilitation	D012046	—	—	—	—	—	—	3	3
Peripheral nervous system diseases	D010523	HP_0009830	G64	—	—	—	—	3	3
Retinal perforations	D012167	EFO_1001028	—	—	—	—	—	3	3
Ganglion cysts	D045888	—	M67.4	—	—	—	—	2	2

Show 142 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Triamcinolone hexacetonide
INN	triamcinolone hexacetonide
Description	Triamcinolone hexacetonide is a corticosteroid hormone.
Classification	Small molecule
Drug class	steroids (not prednisolone derivatives); topical steroids (acetal derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C